For decades, a core assumption in aging biology held that certain molecular scars accumulate irreversibly — that once long-lived proteins in collagen, cartilage, and the lens of the eye became chemically modified by glucose-derived compounds, that damage was permanent. A finding published in Nature Communications directly challenges that premise, with meaningful implications for how we might one day intervene in the biochemistry of aging itself.
The research centers on Nε-carboxymethyl-lysine (CML), one of the most prevalent advanced glycation end products (AGEs) found in aging tissues. CML forms when reactive carbonyl species permanently modify lysine residues on proteins, altering their structure and function. It also binds to RAGE — the receptor for advanced glycation end products — triggering downstream cascades of chronic inflammation and oxidative stress. The investigators engineered a novel enzyme, CMLase, through directed evolution screening of over 500 million variants, ultimately producing a catalyst capable of oxidizing the CML adduct and restoring the native lysine residue. Critically, the enzyme demonstrated activity not only in model protein systems but also in human tissue samples obtained from elderly donors, providing a proof-of-concept that crosses from bench biochemistry into biologically relevant material.
The significance here is hard to overstate as a conceptual advance. Enzymatic repair of stable, end-stage glycation damage would represent a categorically different approach to molecular aging than antioxidant supplementation or AGE-precursor chelation — both of which operate upstream. However, the distance between in vitro tissue demonstration and any therapeutic application remains substantial. Key unknowns include delivery mechanisms to reach long-lived proteins in dense connective tissues, potential immunogenicity of an engineered enzyme, and whether restoring CML-modified proteins structurally rescues their function. This is early-stage but genuinely paradigm-shifting as a proof of concept — the first credible enzymatic reversal of a modification previously considered a one-way street in aging chemistry.
